文献速递中医内科中药与中成药合理使用

脱氢茯苓酸减少巴弗洛霉素A1诱导的PC12细胞β-淀粉样蛋白积聚

Dehydropachymic acid decreases bafilomycin A1 induced β-Amyloid accumulation in PC12 cells.
PubMed 文献 · J Ethnopharmacol · 2017-01-07

本研究探讨茯苓主要三萜成分脱氢茯苓酸(DPA)对巴弗洛霉素A1诱导的PC12-APP细胞中β-淀粉样蛋白(Aβ)清除的影响及机制。DPA在6.25、12.5、25μg/mL浓度下作用4小时后与50nmol/L巴弗洛霉素A1共处理48小时,可显著降低培养基Aβ1-42含量、减少细胞内APP和Aβ1-42积聚,并恢复溶酶体酸化和自噬流。结果提示DPA通过修复溶酶体功能促进Aβ清除,具有阿尔茨海默病治疗潜力。

要点

  • DPA降低巴弗洛霉素A1诱导的PC12-APP细胞培养基Aβ1-42含量。
  • DPA减少细胞内APP和Aβ1-42积聚,且对细胞活力无显著影响。
  • DPA恢复溶酶体酸化与自噬流,机制涉及LC3-II/LC3-I比值和组织蛋白酶D。

核心结论

  • DPA可有效清除巴弗洛霉素A1损伤的PC12细胞中Aβ1-42的积聚,机制为恢复溶酶体酸化和自噬流。
  • 结果提示DPA对阿尔茨海默病具有治疗潜力。

研究设计与样本

  • 体外细胞实验,使用稳定转染pCB6-APP的PC12-APP细胞和稳定转染pSelect-LC3-GFP的PC12-LC3-GFP细胞。
  • DPA浓度6.25、12.5、25μg/mL处理4小时,再与50nmol/L巴弗洛霉素A1共处理48小时(对照除外)。
  • 检测方法包括MTT法、ELISA、Western blotting、荧光显微镜和LysoTracker Red染色。

主要发现

  • DPA对细胞活力无显著影响,但显著降低培养基Aβ1-42含量并消除细胞内APP和Aβ1-42积聚。
  • DPA降低巴弗洛霉素A1升高的LC3-II/LC3-I比值和GFP-LC3斑点。
  • DPA恢复巴弗洛霉素A1引起的溶酶体内部pH升高和mCatD含量降低。

关键数值与推荐

  • DPA使用浓度为6.25、12.5、25μg/mL,作用4小时。
  • 巴弗洛霉素A1使用浓度为50nmol/L,共处理48小时。
  • Aβ1-42含量用ELISA测定,蛋白量以GAPDH为内参归一化。

临床怎么用

  • 提示茯苓三萜成分DPA可能通过溶酶体-自噬途径促进Aβ清除,为AD中药干预提供细胞水平依据。
  • 需进一步体内研究验证DPA的疗效与安全性,暂不能直接推导临床用药方案。

局限性

  • 研究仅为体外细胞实验,未涉及动物模型或临床样本。
  • 未报告DPA的药代动力学、血脑屏障通透性及长期毒性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Fuling, the sclerotium of Poria cocos, was frequently used in traditional Chinese medicine (TCM) formulae for Alzheimer's disease (AD) intervention over the past 10 centuries. And its extracts exhibited significant effects in both cellular and animal models of AD in previous studies. However, its mechanisms on prevention and treatment of AD have not been well elucidated yet. AIM OF THE STUDY: To investigate the effect and corresponding mechanisms of dehydropachymic acid, which is one of the major triterpenes in P. cocos, on the clearance of β-amyloid accumulation in bafilomycin A1 induced PC12 cells. MATERIALS AND METHODS: MTT assay was used to examine the DPA effect on the viability of PC12 cells stable transfected with pCB6-APP (PC12-APP). PC12-APP cells were treated with DPA at the concentration of 6.25, 12.5, 25μg/mL for 4h, and then co-treated with 50nmol/L bafilomycin A1 for 48h except the controls. The Aβ1-42 content in culture medium was determined by ELISA. The intracellular amount of APP, Aβ1-42, LC3, cathepsin D was measured by Western blotting and normalized to GAPDH loading control. The PC12 cells stable transfected with pSelect-LC3-GFP (PC12-LC3-GFP) was used in the fluorescence microscopy estimation of autophagosomes accumulation. The internal pH in lysosome was detected by LysoTracker Red staining. RESULTS: DPA had no significant effect on the cell viability but could significantly decrease Aβ1-42 content in culture medium and eliminate the intracellular accumulation of APP and Aβ1-42 in bafilomycin A1 induced PC12-APP cells. Furthermore, DPA lowered the LC3-II/LC3-I ratio and reduced the GFP-labeled LC3 puncta which were elevated by bafilomycin A1. And the increase in internal pH of lysosome and decrease in mCatD amount in Bafilomycin A1 induced PC12-APP cells were restored by DPA treatment. These results indicated that DPA could restore the lysosomal acidification and recover the autophgic flux which is impaired by bafilomycin A1. CONCLUSIONS: DPA could effectively clear the accumulation of Aβ1-42 in bafilomycin A1 impaired PC12 cells through restoring the lysosomal acidification and recovering the autophgic flux. And these results highlight its therapeutic potential for AD treatment.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Yu M, Xu X, Jiang N, et al. Dehydropachymic acid decreases bafilomycin A1 induced β-Amyloid accumulation in PC12 cells. J Ethnopharmacol. 2017. PMID: 28077330. doi:10.1016/j.jep.2017.01.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。